|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Chicago |
|---|---|
| Collaborator: |
Genzyme |
| Information provided by: | University of Chicago |
| ClinicalTrials.gov Identifier: | NCT00724009 |
Purpose
For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.
| Condition | Intervention |
|---|---|
|
Leukemia |
Drug: Clofarabine |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases. |
| Enrollment: | 29 |
| Study Start Date: | December 2007 |
| Estimated Study Completion Date: | January 2011 |
| Estimated Primary Completion Date: | January 2011 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Adequate hepatobiliary function as indicated by the following laboratory values:
Exclusion Criteria:
Contacts and Locations| United States, Illinois | |
| The University of Chicago hospitals | |
| Chicago, Illinois, United States, 60637 | |
| Principal Investigator: | Wendy Stock, MD | University of Chicago |
More Information
| Responsible Party: | Wendy Stock, MD, Professor, The University of Chicago |
| ClinicalTrials.gov Identifier: | NCT00724009 History of Changes |
| Other Study ID Numbers: | 15809B |
| Study First Received: | July 25, 2008 |
| Last Updated: | September 1, 2010 |
| Health Authority: | United States: Institutional Review Board |
|
Leukemia Myelodysplastic Syndromes Myeloproliferative Disorders Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases |
Hematologic Diseases Clofarabine Antineoplastic Agents Therapeutic Uses Pharmacologic Actions |